Trial Profile
Role of Rituximab Containing Salvage Chemotherapy and in Vivo Purging in Obtaining PCR Negative Leukapheresis Product in Patients With Relapsed Follicular Lymphoma or Transplant Eligible Mantle Cell Lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Follicular lymphoma
- Focus Therapeutic Use
- 19 Apr 2017 Status changed from active, no longer recruiting to completed.
- 31 Mar 2015 Planned End Date changed from 1 Mar 2015 to 1 Jan 2016, as reported by ClinicalTrials.gov.
- 31 Mar 2015 Planned primary completion date changed from 1 Dec 2014 to 1 Sep 2015, as reported by ClinicalTrials.gov.